News | October 27, 2025
Zydus receives approval from Health Canada for Mesalamine suppositories
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
The event will be attended by 35,000+ industry professionals
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
